|LETTERS TO EDITOR
|Year : 2019 | Volume
| Issue : 3 | Page : 295-297
Revisiting Omega and Veraguth's Sign
Anantprakash S Saraf1, Santanu Nath2
1 Department of Psychiatry, Mahatma Gandhi Institute of Medical Sciences, Sevagram, Wardha, Maharashtra, India
2 Department of Psychiatry, AIIMS, Bhubaneswar, Orissa, India
|Date of Web Publication||17-May-2019|
Dr. Anantprakash S Saraf
Department of Psychiatry, Mahatma Gandhi Institute of Medical Sciences, Sevagram, Wardha, Maharashtra
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Saraf AS, Nath S. Revisiting Omega and Veraguth's Sign. Indian J Psychol Med 2019;41:295-7
Omega sign and Veraguth's fold are two facial features classically considered diagnostic of melancholic depression. Despite of their long history and relative objectivity, these valuable signs have been forgotten in current psychiatric practice. We will revisit these signs and their relevance to current knowledge and practice.
Omega sign (also known as “omega melancholicum”) was first described in 1872 by Charles Darwin as “grief muscles” in his book, The Expression of the Emotions in Man and Animals, where he described melancholic depression in graphic details, with precocious biological insights. In 1878, Heinrich Schule, a German psychiatrist, proposed the term “the melancholic omega” for the peculiar furrowing of glabellar skin above the dorsum of the nose. It is called so because it resembles Greek alphabet 'Ω', appearing as two vertical slits between the eyebrows, joined at the top by a horizontal crease. Oswald Bumke described similar facial expression in 1924, among patients with melancholia and also schizophrenia, which he described as the “puzzlement” (Ratlosigkeit).
Veraguth's fold is a similarly important visible sign occurring in chronic depression, which was initially reported by Otto Veraguth around 1911, who observed eyelid folds typically seen in chronic depressive patients. This sign was later popularized by Heinz Lehmann's illustration in Kaplan and Sadock's Comprehensive Textbook of Psychiatry., Veraguth's sign appears as triangular palpebral folds running diagonally from the lateral corners of the eyes, medially upward to the medial end of the eyebrows [Figure 1].,
|Figure 1: Vertical wrinkling between the eyebrows joined at the top by a horizontal crease (Omega sign sign-white arrow); also shows diagonal palpebral folds running medially upward (Veraguth's sign-black arrow)|
Click here to view
Omega sign is formed due to excessive and prolonged contraction of corrugator and procerus muscles, as recorded by electromyography in depressed individuals. It has been proposed that muscular activity in the eyebrow area influences proprioceptive fibers of the optic branch of the trigeminal nerve, which predominantly activate the ipsilateral ventromedial prefrontal cortex through the ipsilateral locus ceruleus, a phenomenon termed as “emotional proprioception.”
From a diagnostic point of view, Omega sign can serve as a useful clinical sign in the face of the unclear and often overlapping cluster of symptoms of the neurotic spectrum of disorders. Veraguth's sign can be useful in differentiating between dementia and pseudo-dementia (depression masking as dementia), which often leads to misdiagnosis and delay in appropriate management. It has also been proposed to use these facial markers digitally for diagnostic and monitoring purposes through computer algorithms and software programs, fostering a new era of use of innovative technology in the medical field.
The therapeutic implication of Omega sign is rapidly gaining popularity in the form of botulinum toxin injections in the glabellar area, leading to a reduction of depressive symptoms, especially in cases of blepharospasm., The most plausible and widely accepted explanation for this therapeutic effect is “the facial feedback hypothesis” ( first proposed by Charles Darwin and William James), which postulates that facial expression influences emotional perception, thus regulating our mood state. Alternative explanations include elevation in mood because of improved social connectivity and feedback because of a more positive reciprocal firing of mirror neurons. It has also been proposed, on the basis of rat models, that botulinum toxin is directly transported by the trigeminal nerve into the amygdala and exerts direct central pharmacological effects. After the procedure, anti-depressive effects start appearing as early as 2 weeks and often last as long as 6 months, well beyond the cosmetic and esthetic effects. Common adverse effects include drooping of eyelids, bruising, erythema, and pain at the injection site, which are transient and reversible.
The diagnostic specificity of Omega sign is limited because of overlap with similar “signs” in neurology and other dystonias. “Procerus sign” is a similar neurological sign reported in atypical parkinsonism, especially progressive supranuclear palsy, characterized by contraction of corrugator supercilii and procerus muscles, leading to vertical wrinkling on the forehead. This lack of specificity and overlap with other conditions limits its value as a stand-alone clinical sign, but nevertheless, it is quite useful when used in conjunction with proper detailed history and thorough mental status examination.
In the wake of current progress in the neurobiological understanding of mental illness, we are moving toward more objective tools for diagnosis and exploring new paradigms for better management of mental illness. In this context, the Omega sign and the Veraguth's fold assume new relevance in both diagnostic and therapeutic domains.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Taylor MA, Fink M. Melancholia: The Diagnosis, Pathophysiology, and Treatment of Depressive Illness. 1st
ed. Cambridge, UK: Cambridge University Press; 2006. p. 87.
Shorter E. Darwin's contribution to psychiatry. British J Psychiatry 2009;195:473-4.
McDaniel WW, Brar B, Srirama M, Shaikh S, Kaur A. Prevalence of Veraguth's eyelid folds during depression in different ethnic groups. J Nerv Ment Dis 2004;192:705-7.
Sadock BJ, Sadock VA, Ruiz P, Kaplan HI. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 10th
ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2017. p. 1636.
Greden JF, Genero N, Price HL. Agitation-increased electromyogram activity in the corrugator muscle region: Apossible explanation of the “Omega sign”? Am J Psychiatry 1985;142:348-51.
Finzi E, Rosenthal NE. Emotional proprioception: Treatment of depression with afferent facial feedback. J Psychiatr Res 2016;80:93-6.
Zapotoczky HG. Problems of differential diagnosis between depressive pseudodementia and Alzheimer's disease. In: Jellinger K, Fazekas F, Windisch M, editors. Ageing and Dementia. 1st
ed. Vienna: Springer Vienna; 1998. p. 93.
Pampouchidou A, Marias K, Tsiknakis M, Simos P, Yang F, Meriaudeau F. Designing a framework for assisting depression severity assessment from facial image analysis. In: Signal and Image Processing Applications (ICSIPA), 2015 IEEE International Conference, IEEE, Oct 19, 2015.p. 578-83.
Finzi E, Rosenthal NE. Treatment of depression with onabotulinumtoxin A: Arandomised, double-blind, placebo controlled trial. J Psychiatr Res 2014;52:1-6.
Chugh S, Chhabria A, Jung S, Kruger TH, Wollmer MA. Botulinum toxin as a treatment for depression in a real-world setting. J Psychiatr Pract 2018;24:15-20.
Magid M, Reichenberg J. Botulinum toxin for depression? An idea that's raising some eyebrows. Curr Psychiatry 2015;14:43-56.
Bhattacharjee S. Procerus sign: Mechanism, clinical usefulness, and controversies. Ann Indian Acad Neurol 2018;21:164-5.
] [Full text]